Literature DB >> 24145475

Prostate cancer: patient-reported outcomes of first-line abiraterone therapy.

Robert Phillips.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24145475     DOI： 10.1038/nrurol.2013.236

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  2 in total

1.  Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.

Authors:  Ethan Basch; Karen Autio; Charles J Ryan; Peter Mulders; Neal Shore; Thian Kheoh; Karim Fizazi; Christopher J Logothetis; Dana Rathkopf; Matthew R Smith; Paul N Mainwaring; Yanni Hao; Thomas Griffin; Susan Li; Michael L Meyers; Arturo Molina; Charles Cleeland
Journal:  Lancet Oncol       Date:  2013-09-25       Impact factor: 41.316

2.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245
  2 in total
  1 in total

Review 1.  Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.

Authors:  Joelle El-Amm; Rami Nassabein; Jeanny B Aragon-Ching
Journal:  Cancer Manag Res       Date:  2017-07-11       Impact factor: 3.989
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.